Back to top
more

Novavax (NVAX)

(Delayed Data from NSDQ)

$8.39 USD

8.39
4,659,131

-0.17 (-1.99%)

Updated Sep 17, 2025 04:00 PM ET

After-Market: $8.42 +0.03 (0.36%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (97 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Novavax's (NVAX) COVID-19 Vaccine Shows 90% Efficacy in US Study

by Zacks Equity Research

Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, shows an overall efficacy of 90% in the phase III PREVENT-19 study in the United States and Mexico.

Zacks Equity Research

Why Is Novavax (NVAX) Up 43.9% Since Last Earnings Report?

by Zacks Equity Research

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Is First Trust Multi Cap Growth AlphaDEX ETF (FAD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FAD

Zacks Equity Research

Novavax's (NVAX) Q1 Loss Widens, Revenues Beat, Shares Down

by Zacks Equity Research

Novavax (NVAX) reports wider-than-expected loss in the first quarter of 2021 while revenues beat estimates. Shares fall in after-hours trading.

Zacks Equity Research

Devon Energy, Bilibili, Novavax, Roblox and Wynn Resorts highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Devon Energy, Bilibili, Novavax, Roblox and Wynn Resorts highlighted as Zacks Bull and Bear of the Day

Mark Vickery headshot

Indexes Sink into Close, Q1 Reports for NVAX, WYNN & More

by Mark Vickery

The Nasdaq was -2.55% Monday, its worst single trading day in almost two months.

Zacks Equity Research

Novavax (NVAX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Novavax (NVAX) delivered earnings and revenue surprises of -15.09% and 53.23%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Novavax (NVAX) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Novavax (NVAX) closed at $160.50, marking a -8.81% move from the previous day.

Zacks Equity Research

Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q1

by Zacks Equity Research

Endo's (ENDP) earnings and sales beat estimates in the first quarter, driven by revived demand.

Sweta Jaiswal, FRM headshot

Top COVID-19 Vaccine Stories of April Put Biotech ETFs in Focus

by Sweta Jaiswal, FRM

Let's take a look at some top coronavirus vaccine stories of April and the possible impact they can have on biotech ETFs.

Zacks Equity Research

Novavax (NVAX) Stock Moves -0.25%: What You Should Know

by Zacks Equity Research

In the latest trading session, Novavax (NVAX) closed at $236.93, marking a -0.25% move from the previous day.

Sanghamitra Saha headshot

Novavax Vaccine to Get U.S. Approval? ETFs to Benefit

by Sanghamitra Saha

Novavax (NVAX) is reportedly set to receive the fourth authorization for COVID-19 vaccine in the United States.

Zacks Equity Research

Is First Trust Multi Cap Growth AlphaDEX ETF (FAD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FAD

Zacks Equity Research

Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Novavax's (NVAX) upcoming first-quarter earnings call, investor focus is expected to be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.

Zacks Equity Research

Novavax (NVAX) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Novavax (NVAX) closed at $207.61, marking a +0.15% move from the previous day.

Zacks Equity Research

Novavax (NVAX) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Novavax (NVAX) closed at $202.09, marking a +0.37% move from the previous day.

Zacks Equity Research

Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Novavax (NVAX) closed at $179.74 in the latest trading session, marking a +1.97% move from the prior day.

Sweta Jaiswal, FRM headshot

Top COVID-19 Vaccine Stories of March Put Biotech ETFs in Focus

by Sweta Jaiswal, FRM

Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.

Zacks Equity Research

Company News for Apr 7, 2021

by Zacks Equity Research

Companies in The News Are: ILMN, NVAX, MRNA, BP.

Zacks Equity Research

Is the Options Market Predicting a Spike in Novavax (NVAX) Stock?

by Zacks Equity Research

Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

Zacks Equity Research

Novavax (NVAX) Stock Moves -0.25%: What You Should Know

by Zacks Equity Research

In the latest trading session, Novavax (NVAX) closed at $173.32, marking a -0.25% move from the previous day.

Sweta Jaiswal, FRM headshot

Will ETFs Gain on AstraZeneca's Latest Covid-19 Vaccine Update?

by Sweta Jaiswal, FRM

Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence thanks to multiple mutants.

Neena Mishra headshot

Follow Dave Portnoy & Reddit Rebellion with These ETFs

by Neena Mishra

These ETFs track social media sentiment & market trends.

Kevin Cook headshot

Bull of the Day: Meridian Bioscience (VIVO)

by Kevin Cook

Delay in FDA approval for latest COVID test hasn't altered growth or value at 3X sales

Zacks Equity Research

Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Novavax (NVAX) closed at $225.46, marking a +1.45% move from the previous day.